Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more?

Breast J. 2020 Jul;26(7):1458-1460. doi: 10.1111/tbj.13740. Epub 2019 Dec 31.
No abstract available

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms* / drug therapy
  • Female
  • Humans
  • Piperazines / therapeutic use
  • Pyridines / therapeutic use

Substances

  • Piperazines
  • Pyridines
  • palbociclib